Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Vivos Therapeutics Inc (VVOS)

$0.42 +0.01 (1.62%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	5.74M
Revenue (ttm)	17.44M
Net Income (ttm)	-21.17M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-121.39%
Debt to Equity Ratio	-6.08

Volume	131,500
Avg Vol	1,999,966
Day's Range	N/A - N/A
Shares Out	13.90M
Stochastic %K	36%
Beta	6.16
Analysts	Sell
Price Target	$2.12

Company Profile

Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test...

Industry: Medical Devices

Sector: Healthcare

Phone: 866 908 4867

Website: www.vivos.com

Address:

7921 Southpark Plaza, Suite 210, Littleton, United States

AMP19 Jul. 17 at 3:26 PM

$VVOS calling the bottom here.

1 · Reply

AMP19 Jul. 17 at 3:25 PM

$VVOS added

0 · Reply

Giovannirs3 Jul. 17 at 2:46 PM

$VVOS 👌

0 · Reply

Loopi Jul. 17 at 2:10 PM

$VVOS lol where is the CEO 😂🔴🔴❗️

0 · Reply

Giovannirs3 Jul. 17 at 1:40 PM

$VVOS ➖️🤗💯

0 · Reply

Giovannirs3 Jul. 17 at 1:40 PM

$VVOS 👎

0 · Reply

Giovannirs3 Jul. 17 at 1:39 PM

$VVOS 👎

0 · Reply

kemsma62 Jul. 17 at 9:18 AM

$VVOS As I said before, personally, I don’t like reverse splits. Based on my experience, most penny stocks continue to decline after a reverse split. Therefore, I hope that we can recover the share price and get above the $1 level before, or no later than after the next earnings report in August. I believe a strong earnings report could help improve investor confidence and support the stock price recovery. 🤞

0 · Reply

ka1954 Jul. 17 at 2:07 AM

$VVOS people here worried about RS and whatnot. Company has about 10 months before they have to worry nasdaq compliance for the $1 rule.

1 · Reply

Loopi Jul. 16 at 6:48 PM

$VVOS before RS will visit $0.11 😂🫵

0 · Reply

Vivos Therapeutics price target lowered to 75c from $1.75 at Alliance Global

2026-06-30T13:35:46.000Z - 18 days ago

Vivos Therapeutics says Vida oral appliance improves insomnia in study

Jun 30, 2026, 8:45 AM EDT - 18 days ago

Vivos' Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants

Jun 22, 2026, 8:30 AM EDT - 26 days ago

Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity

2026-06-11T12:55:08.000Z - 5 weeks ago

Vivos Therapeutics intends to file registration statement for rights offering

Jun 11, 2026, 8:30 AM EDT - 5 weeks ago

Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering

2026-06-10T13:18:43.000Z - 5 weeks ago

Vivos Therapeutics enters pact with South Palm Cardiovascular Associates

Jun 10, 2026, 9:03 AM EDT - 5 weeks ago

Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients

Jun 9, 2026, 11:30 AM EDT - 5 weeks ago

Vivos Therapeutics Transcript: WTR Insights Conference: Powered by The Small Cap Showcase

Jun 8, 2026, 1:39 PM EDT - 5 weeks ago

Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026

Jun 5, 2026, 8:45 AM EDT - 6 weeks ago

Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing

2026-05-20T20:22:09.000Z - 2 months ago

Vivos Therapeutics reports Q1 EPS (52c), consensus (45c)

May 20, 2026, 4:10 PM EDT - 2 months ago

Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update

May 20, 2026, 4:00 PM EDT - 2 months ago

Vivos Therapeutics Quarterly report: Q1 2026

May 20, 2026, 4:00 PM EDT - 2 months ago

Vivos Therapeutics Earnings release: Q1 2026

May 9, 2026, 11:53 AM EDT - 2 months ago

Analysts see 200%+ upside in these 3 high-risk stocks: here's why?

ACTU ATAI

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Vivos Therapeutics Registration statement: Registration filing

2026-04-17T13:52:17.000Z - 3 months ago

Vivos Therapeutics price target lowered to $2.50 from $7 at H.C. Wainwright

2026-04-17T12:43:47.000Z - 3 months ago

Vivos Therapeutics price target lowered to $1.75 from $2.50 at Alliance Global

Apr 15, 2026, 5:00 PM EDT - 3 months ago

Vivos Therapeutics Earnings Call Transcript: Q4 2025

Apr 15, 2026, 5:00 PM EDT - 3 months ago

Vivos Therapeutics Earnings release: Q4 2025

Apr 15, 2026, 5:00 PM EDT - 3 months ago

Vivos Therapeutics Annual report: Q4 2025

Apr 15, 2026, 4:20 PM EDT - 3 months ago

Vivos Therapeutics Reports Full Year 2025 Financial Results

Apr 15, 2026, 8:45 AM EDT - 3 months ago

Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call

Apr 7, 2026, 8:45 AM EDT - 3 months ago

Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners

Mar 26, 2026, 8:45 AM EDT - 4 months ago

Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market

2026-03-17T13:00:18.000Z - 4 months ago

Vivos Therapeutics’ oral medical devices proven to enhance airways

Mar 17, 2026, 8:45 AM EDT - 4 months ago

Recent Study Confirms Fundamental Correlation Between Severity of Obstructive Sleep Apnea and Oral Anatomy

Feb 17, 2026, 7:00 AM EST - 5 months ago

Vivos Therapeutics Registration statement: Registration Filing

2026-02-17T11:15:45.000Z - 5 months ago

Vivos Therapeutics files to sell 3.96M shares of common stock for holders

2026-02-05T13:50:40.000Z - 5 months ago

Vivos, SoundHealth collaborate to expand access to SoundHealth’s technology

2026-02-05T13:50:12.000Z - 5 months ago

Vivos Therapeutics signs 12-part media series with New to the Street

Feb 5, 2026, 8:45 AM EST - 5 months ago

Vivos Therapeutics and SoundHealth Announce Collaboration to Expand Access to SoundHealth's Groundbreaking FDA-Cleared Allergy and Sleep Technologies

Jan 20, 2026, 5:31 PM EST - 6 months ago

Vivos Therapeutics Announces Closing of Exercise of Warrants for $4.64 Million Gross Proceeds

2026-01-16T13:10:49.000Z - 6 months ago

Vivos Therapeutics announces exercise of warrants for $4.64M gross proceeds

Jan 16, 2026, 8:00 AM EST - 6 months ago

Vivos Therapeutics Announces Exercise of Warrants for $4.64 Million Gross Proceeds

Dec 16, 2025, 11:00 AM EST - 7 months ago

Vivos Therapeutics Transcript: Fireside Chat

2025-12-16T13:50:29.000Z - 7 months ago

Vivos Therapeutics opens sleep center in Auburn Hills, Michigan

Dec 16, 2025, 8:45 AM EST - 7 months ago

Vivos Therapeutics Announces Grand Opening of Affiliated Sleep Center Near Detroit, Michigan

Nov 19, 2025, 5:00 PM EST - 8 months ago

Vivos Therapeutics Earnings Call Transcript: Q3 2025

Nov 19, 2025, 5:00 PM EST - 8 months ago

Vivos Therapeutics Earnings release: Q3 2025

Nov 19, 2025, 5:00 PM EST - 8 months ago

Vivos Therapeutics Quarterly report: Q3 2025

2025-11-19T21:30:18.000Z - 8 months ago

Vivos Therapeutics reports Q3 EPS (49c), consensus (51c)

Nov 19, 2025, 4:20 PM EST - 8 months ago

Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025

Nov 19, 2025, 8:30 AM EST - 8 months ago

Vivos Therapeutics Schedules Release of Third Quarter 2025 Financial Results and Conference Call

2025-11-17T11:15:44.000Z - 8 months ago

Vivos Therapeutics initiated with a Buy at H.C. Wainwright

2025-09-30T12:45:33.000Z - 10 months ago

Vivos Therapeutics announces additional data from use of Vivos DNA device

Sep 30, 2025, 8:30 AM EDT - 10 months ago

Vivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD from Use of Vivos DNA Device

Sep 29, 2025, 8:00 AM EDT - 10 months ago

Vivos Therapeutics Proxy statement: Proxy Filing

2025-09-17T12:41:24.000Z - 10 months ago

Vivos Therapeutics announces trial results in pediatric OSA treatment

Sep 17, 2025, 8:30 AM EDT - 10 months ago

Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment

Sep 5, 2025, 8:00 AM EDT - 11 months ago

Vivos Therapeutics Registration statement: Registration Filing

Aug 19, 2025, 5:00 PM EDT - 11 months ago

Vivos Therapeutics Earnings Call Transcript: Q2 2025

Aug 19, 2025, 5:00 PM EDT - 11 months ago

Vivos Therapeutics Earnings release: Q2 2025

Aug 19, 2025, 5:00 PM EDT - 11 months ago

Vivos Therapeutics Quarterly report: Q2 2025

Aug 19, 2025, 4:20 PM EDT - 11 months ago

Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

Aug 19, 2025, 8:30 AM EDT - 11 months ago

Vivos Therapeutics Schedules Release of Second Quarter 2025 Financial Results and Conference Call

2025-07-30T12:50:50.000Z - 1 year ago

Vivos Therapeutics appoints Bruhn as EVP, Jones as SVP

2025-07-01T12:40:14.000Z - 1 year ago

Vivos Therapeutics receives Medicare approval for VidaSleep Oral Applicance

2025-06-26T12:40:25.000Z - 1 year ago

Vivos announces results published of OSA using Daytime-Nighttime Appliance

Jun 26, 2025, 8:30 AM EDT - 1 year ago

New Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in Children

May 15, 2025, 5:00 PM EDT - 1 year ago

Vivos Therapeutics Earnings Call Transcript: Q1 2025

May 15, 2025, 5:00 PM EDT - 1 year ago

Vivos Therapeutics Earnings release: Q1 2025

May 15, 2025, 5:00 PM EDT - 1 year ago

Vivos Therapeutics Quarterly report: Q1 2025

May 14, 2025, 9:15 AM EDT - 1 year ago

Vivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference Call

Apr 16, 2025, 8:30 AM EDT - 1 year ago

Vivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in Nevada

Mar 31, 2025, 5:00 PM EDT - 1 year ago

Vivos Therapeutics Earnings Call Transcript: Q4 2024

Mar 31, 2025, 5:00 PM EDT - 1 year ago

Vivos Therapeutics Earnings release: Q4 2024

Mar 31, 2025, 5:00 PM EDT - 1 year ago

Vivos Therapeutics Annual report: Q4 2024

Mar 31, 2025, 4:20 PM EDT - 1 year ago

Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update

Mar 28, 2025, 8:30 AM EDT - 1 year ago

Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call

Feb 18, 2025, 12:00 PM EST - 1 year ago

Vivos Therapeutics Transcript: Fireside Chat

Feb 11, 2025, 7:00 AM EST - 1 year ago

Vivos Therapeutics Registration statement: Registration Filing

Jan 29, 2025, 7:00 AM EST - 1 year ago

Vivos Therapeutics Registration statement: Registration Filing

Jan 22, 2025, 7:00 AM EST - 1 year ago

Vivos Therapeutics Registration statement: Registration Filing

Dec 23, 2024, 8:00 AM EST - 1 year ago

Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 14, 2024, 5:00 PM EST - 1 year ago

Vivos Therapeutics Earnings Call Transcript: Q3 2024

Nov 14, 2024, 5:00 PM EST - 1 year ago

Vivos Therapeutics Earnings release: Q3 2024

Nov 14, 2024, 5:00 PM EST - 1 year ago

Vivos Therapeutics Quarterly report: Q3 2024

Nov 13, 2024, 5:00 PM EST - 1 year ago

Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call

Nov 6, 2024, 7:00 AM EST - 1 year ago

Vivos Therapeutics Proxy statement: Proxy Filing

Oct 8, 2024, 7:30 AM EDT - 1 year ago

Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association

Oct 7, 2024, 8:00 AM EDT - 1 year ago

Vivos Therapeutics Proxy statement: Proxy Filing

Sep 18, 2024, 7:00 AM EDT - 1 year ago

Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring

Aug 14, 2024, 5:00 PM EDT - 2 years ago

Vivos Therapeutics Earnings Call Transcript: Q2 2024

Aug 14, 2024, 5:00 PM EDT - 2 years ago

Vivos Therapeutics Quarterly report: Q2 2024

Aug 14, 2024, 5:00 PM EDT - 2 years ago

Vivos Therapeutics Earnings release: Q2 2024

Aug 14, 2024, 4:05 PM EDT - 2 years ago

Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

Aug 14, 2024, 7:30 AM EDT - 2 years ago

Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call

Jul 30, 2024, 8:00 AM EDT - 2 years ago

Vivos Therapeutics Registration statement: Registration Filing

Jun 27, 2024, 7:30 AM EDT - 2 years ago

Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model

Jun 12, 2024, 7:30 AM EDT - 2 years ago

Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance

May 14, 2024, 5:00 PM EDT - 2 years ago

Vivos Therapeutics Earnings Call Transcript: Q1 2024

May 14, 2024, 5:00 PM EDT - 2 years ago

Vivos Therapeutics Quarterly report: Q1 2024

May 14, 2024, 5:00 PM EDT - 2 years ago

Vivos Therapeutics Earnings release: Q1 2024

May 14, 2024, 4:05 PM EDT - 2 years ago

Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update

May 14, 2024, 7:30 AM EDT - 2 years ago

Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call

Apr 22, 2024, 8:00 AM EDT - 2 years ago

Vivos Therapeutics Registration statement: Registration Filing

Apr 9, 2024, 8:00 AM EDT - 2 years ago

Vivos Therapeutics Registration statement: Registration Filing

Apr 9, 2024, 7:30 AM EDT - 2 years ago

Vivos Therapeutics' Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement

Mar 28, 2024, 5:00 PM EDT - 2 years ago

Vivos Therapeutics Earnings Call Transcript: Q4 2023

Mar 28, 2024, 5:00 PM EDT - 2 years ago

Vivos Therapeutics Earnings release: Q4 2023

Mar 28, 2024, 5:00 PM EDT - 2 years ago

Vivos Therapeutics Annual report: Q4 2023

Mar 28, 2024, 4:05 PM EDT - 2 years ago

Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update

Mar 28, 2024, 7:30 AM EDT - 2 years ago

Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call

Feb 6, 2024, 7:30 AM EST - 2 years ago

Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities

Jan 8, 2024, 7:30 AM EST - 2 years ago

Vivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company's Proprietary Oral Medical Devices to Treat Severe OSA

Dec 11, 2023, 7:30 AM EST - 2 years ago

Vivos Therapeutics Presents Groundbreaking Event: “Empowering Women to Champion Airway”

Nov 30, 2023, 7:00 AM EST - 2 years ago

Vivos Therapeutics Registration statement: Registration Filing

Nov 29, 2023, 11:09 AM EST - 2 years ago

Vivos Therapeutics' stock soars as sleep apnea device gets regulatory clearance

Nov 29, 2023, 7:44 AM EST - 2 years ago

US FDA clears Vivos Therapeutics' oral device treatment for sleep apnea

Nov 29, 2023, 7:30 AM EST - 2 years ago

Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea

Nov 22, 2023, 7:00 AM EST - 2 years ago

Vivos Therapeutics Registration statement: Registration Filing

Nov 14, 2023, 5:00 PM EST - 2 years ago

Vivos Therapeutics Earnings Call Transcript: Q3 2023

Nov 14, 2023, 5:00 PM EST - 2 years ago

Vivos Therapeutics Quarterly report: Q3 2023

Nov 14, 2023, 5:00 PM EST - 2 years ago

Vivos Therapeutics Earnings release: Q3 2023

Nov 14, 2023, 4:05 PM EST - 2 years ago

Vivos Therapeutics Reports Third Quarter 2023 Financial Results and Provides Operational Update

Nov 9, 2023, 4:30 PM EST - 2 years ago

Vivos Therapeutics Schedules Release of Third Quarter 2023 Financial Results and Conference Call

Nov 2, 2023, 5:00 PM EDT - 2 years ago

Vivos Therapeutics Closes $4 Million Private Placement

AMP19 Jul. 17 at 3:26 PM

$VVOS calling the bottom here.

1 · Reply

AMP19 Jul. 17 at 3:25 PM

$VVOS added

0 · Reply

Giovannirs3 Jul. 17 at 2:46 PM

$VVOS 👌

0 · Reply

Loopi Jul. 17 at 2:10 PM

$VVOS lol where is the CEO 😂🔴🔴❗️

0 · Reply

Giovannirs3 Jul. 17 at 1:40 PM

$VVOS ➖️🤗💯

0 · Reply

Giovannirs3 Jul. 17 at 1:40 PM

$VVOS 👎

0 · Reply

Giovannirs3 Jul. 17 at 1:39 PM

$VVOS 👎

0 · Reply

kemsma62 Jul. 17 at 9:18 AM

0 · Reply

ka1954 Jul. 17 at 2:07 AM

$VVOS people here worried about RS and whatnot. Company has about 10 months before they have to worry nasdaq compliance for the $1 rule.

1 · Reply

Loopi Jul. 16 at 6:48 PM

$VVOS before RS will visit $0.11 😂🫵

0 · Reply

Loopi Jul. 16 at 6:36 PM

$VVOS All stocks jumped already and this here lol going for Reverse Split soon 😅🔜🔴

0 · Reply

Loopi Jul. 16 at 4:19 PM

$VVOS Let’s see new low under $0.38 😅🔴❗️

0 · Reply

Giovannirs3 Jul. 16 at 2:25 PM

$VVOS dirty title🤡

0 · Reply

Giovannirs3 Jul. 16 at 2:24 PM

$VVOS This scam isn't worth four million, it's worth zero! Yet another 1-for-100 reverse split!🤗💯👎

0 · Reply

Giovannirs3 Jul. 16 at 2:11 PM

$VVOS ➖️💯👇👍👎👎👎🤣

0 · Reply

Giovannirs3 Jul. 16 at 2:05 PM

$VVOS 🤣🤣🤣🤣🤣👎👎👎👎👎👎

0 · Reply

GamblerDan Jul. 15 at 10:54 PM

$VVOS Skaff gonna get a board seat next

1 · Reply

GamblerDan Jul. 15 at 9:56 PM

$VVOS https://www.sec.gov/Archives/edgar/data/1716166/000110465926083931/xslSCHEDULE_13D_X02/primary_doc.xml

0 · Reply

Loopi Jul. 15 at 9:39 PM

$VVOS One Thing in this Market avoid stocks that move Post-market 🔴 follow this

0 · Reply

Loopi Jul. 15 at 9:36 PM

$VVOS The CEO will keep laying and Optimistic stupid still believe him. Stock Price Action represents the company execution Be aware 🔴👉🔜❗️

0 · Reply

Loopi Jul. 15 at 9:34 PM

$VVOS sell on any kind of news because the stock going for reverse split very soon this year 😆🔴❗️

0 · Reply

PrimeZoneNews Jul. 15 at 9:28 PM

$VVOS 13D 2,783,102 19.90%

0 · Reply

1.0.0